| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.05 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.05 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.098 | 0.05 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.05 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.05 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.05 |
| mRNA | BIBR-1532 | CTRPv2 | pan-cancer | AAC | 0.07 | 0.05 |
| mRNA | TPCA-1 | GDSC1000 | pan-cancer | AAC | 0.054 | 0.05 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.05 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.07 | 0.06 |